Daniel Lowe, MD
Urology · Clifton, NJNPI 1932373578
Payments from drug & device makers
Across 152 payments — averaging $28.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Blue Earth Diagnostics$894
- Astellas Pharma US Inc$605
- Procept Biorobotics Corporation$401
- Boston Scientific$342
- AbbVie$234
- EDAP Technomed Inc$218
- plus $2K from 31 others
What the payments were for
- Consulting fees$68816%
- Food & beverage$3,19574%
- Education$42910%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Blue Earth Diagnostics | 11 | $894 |
| Astellas Pharma US Inc | 21 | $605 |
| Procept Biorobotics Corporation | 5 | $401 |
| Boston Scientific | 6 | $342 |
| AbbVie(2 entities) | 9 | $234 |
| EDAP Technomed Inc | 6 | $218 |
| Pfizer | 11 | $147 |
| Endo Pharmaceuticals Inc. | 9 | $144 |
| Neotract Inc. | 3 | $136 |
| Bayer | 9 | $136 |
| Olympus America Inc. | 5 | $97 |
| SRS Medical Systems, Inc. | 2 | $87 |
| Tolmar Pharmaceuticals, Inc. | 6 | $80 |
| Myovant Sciences Inc. | 4 | $61 |
| AstraZeneca | 4 | $58 |
| C. R. Bard, Inc. & Subsidiaries | 3 | $56 |
| Merck | 4 | $53 |
| Dendreon Pharmaceuticals LLC | 3 | $45 |
| Laborie Medical Technologies Corp. | 1 | $42 |
| Dentsply IH Inc. | 3 | $42 |
| Ferring Pharmaceuticals Inc. | 3 | $40 |
| Sun Pharmaceutical Industries Inc. | 3 | $35 |
| Rochester Medical Corporation | 2 | $34 |
| Medtronic | 2 | $34 |
| Janssen Scientific Affairs, LLC | 1 | $31 |
| Myriad Genetic Laboratories, Inc. | 2 | $31 |
| Tempus AI, Inc | 1 | $30 |
| Johnson & Johnson | 2 | $29 |
| Sumitomo Pharma America, Inc. | 2 | $28 |
| Hollister Incorporated | 2 | $27 |
| Urogen Pharma, Inc. | 1 | $21 |
| Endo USA, Inc. | 1 | $18 |
| Tolmar, Inc. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $15 |
| Aytu Biopharma, Inc. | 1 | $14 |
| Mission Pharmacal Company | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axumin$688
- AquaBeam Robotic System$315
- Mavyret$123
- GENERAL KIDNEY STONE DISEASE$120
How this compares
$4,311 in reported general payments places this provider in the 65th percentile of 401 urology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 251 | $201,716 |
| MyrbetriqMirabegron | 207 | $133,613 |
| AveedTestosterone Undecanoate | 17 | $31,808 |
| Tamsulosin Hcl | 1,428 | $29,374 |
| Finasteride | 1,214 | $17,501 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 303 | $7,408 |
| Silodosin | 82 | $6,427 |
| Potassium Citrate ErPotassium Citrate | 39 | $5,867 |
| Solifenacin Succinate | 105 | $5,691 |
| Dutasteride | 74 | $3,118 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 21 | $3,009 |
| Tadalafil | 24 | $1,895 |
| Oxybutynin Chloride ErOxybutynin Chloride | 56 | $1,380 |
| Ciprofloxacin Hcl | 189 | $1,048 |
| Cephalexin | 68 | $661 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $28 | $201,716251 claims |
| Astellas Pharma US IncMyrbetriq | $605 | $133,613207 claims |
| Endo Pharmaceuticals Inc.Aveed | $144 | $31,80817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 401 urology providers in New Jersey.
Other urology in Clifton
- Karl CoutinhoClifton$100K
- Ephrem OlwenyClifton$87K
- Gordon BrownCherry Hill$2.8M
- Nitin YerramHackensack$1.6M
- Michael StifelmanHackensack$1.5M
- Thomas MuellerLinwood$1.2M
- David SussmanLinwood$833K
- Michael IngberDenville$607K
- Ravi MunverHackensack$529K
- Grannum SantBridgewater$487K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.